Hospital
Ascension Borgess Hospital
Ascension Borgess Hospital was paid $4.84M by Medicaid between Jan 2018 and Dec 2024, across 96 billing codes. Its largest line is 99283, emergency room visit (moderate) — 37% of everything it billed.
33Billing provider infoASCENSION BORGESS HOSPITAL
PLAINWELL, MI 49080
PLAINWELL, MI 49080
33aNPI1154504892assigned 12/17/2007
33bProvider typeSpecial Hospital
28Total paid$4.84M
24GClaims129,213
24DCodes billed96
24AFirst – last monthJan 2018 – Dec 2024
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official HOUGHTON, MARINA controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 19,644 | $655K | |
| 2019 | 16,508 | $630K | |
| 2020 | 13,985 | $513K | |
| 2021 | 18,585 | $702K | |
| 2022 | 24,639 | $846K | |
| 2023 | 24,016 | $902K | |
| 2024incomplete | 11,836 | $596K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 37% | 14,724 | 13,892 | $1.81M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 25% | 6,770 | 6,306 | $1.22M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 13% | 2,358 | 2,248 | $606K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 6.4% | 3,141 | 2,906 | $311K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 4.4% | 2,983 | 2,922 | $212K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 2.0% | 4,429 | 1,280 | $97K |
| 71046 | Radiologic examination, chest; 2 views | 1.5% | 2,086 | 2,021 | $75K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.5% | 398 | 390 | $71K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.3% | 2,328 | 2,145 | $65K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 3,068 | 1,017 | $46K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,450 | 1,425 | $43K |
| 71045 | Radiologic examination, chest; single view | <1% | 757 | 743 | $33K |
84 more codes
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 4,172 | $31K |
| 80053 | Comprehensive metabolic panel | <1% | 9,713 | $28K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 1,967 | $27K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 811 | $22K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 10,919 | $22K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 95 | $12K |
| 80061 | Lipid panel | <1% | 1,336 | $11K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 116 | $10K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,917 | $9K |
| 97162 | <1% | 143 | $6K | |
| 83718 | <1% | 1,620 | $5K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 8,786 | $5K |
| 82728 | <1% | 758 | $5K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 2,364 | $5K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 122 | $4K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 1,720 | $4K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 37 | $4K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 146 | $3K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 67 | $3K |
| 84478 | <1% | 1,341 | $3K | |
| 82465 | <1% | 1,632 | $3K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 162 | $2K |
| 81001 | <1% | 5,807 | $2K | |
| 73630 | <1% | 247 | $2K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,758 | $2K |
| 73610 | <1% | 193 | $2K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 48 | $1K |
| 73562 | <1% | 123 | $1K | |
| 85027 | <1% | 507 | $1K | |
| 82607 | <1% | 178 | $1K | |
| 83690 | <1% | 2,024 | $1K | |
| 84439 | <1% | 201 | $955.91 | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 143 | $949.74 |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 143 | $949.74 |
| 83540 | <1% | 316 | $945.77 | |
| 83735 | <1% | 465 | $908.08 | |
| 74018 | <1% | 24 | $897.74 | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 201 | $869.34 |
| 73030 | <1% | 51 | $832.19 | |
| 84703 | <1% | 2,719 | $799.44 | |
| 73130 | <1% | 97 | $779.65 | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 13 | $764.05 |
| 84484 | <1% | 1,271 | $737.69 | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 12 | $722.96 |
| 85610 | <1% | 444 | $623.08 | |
| 83550 | <1% | 119 | $584.66 | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 368 | $510.96 |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 974 | $505.17 |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 39 | $478.15 |
| 85651 | <1% | 273 | $464.46 | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 351 | $349.67 |
| 87186 | <1% | 268 | $342.03 | |
| 82043 | <1% | 116 | $324.80 | |
| 83605 | <1% | 221 | $304.77 | |
| 73110 | <1% | 27 | $293.66 | |
| 86140 | <1% | 121 | $273.89 | |
| 87254 | <1% | 118 | $267.46 | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 26 | $264.65 |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 2,711 | $235.72 |
| 87486 | <1% | 12 | $231.46 | |
| 87581 | <1% | 12 | $231.46 | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 12 | $231.46 |
| 84702 | <1% | 36 | $219.29 | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 1,100 | $201.14 |
| 87430 | <1% | 864 | $196.11 | |
| 72100 | <1% | 12 | $178.92 | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 13 | $173.33 |
| 87077 | <1% | 48 | $94.17 | |
| 83880 | <1% | 16 | $78.50 | |
| 85730 | <1% | 38 | $65.86 | |
| 86592 | <1% | 39 | $55.12 | |
| 86703 | <1% | 38 | $51.66 | |
| 85379 | <1% | 48 | $48.01 | |
| 87634 | <1% | 168 | $46.24 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | 0% | 3,472 | $0.00 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 0% | 498 | $0.00 |
| J1170 | Injection, hydromorphone, up to 4 mg | 0% | 133 | $0.00 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 0% | 42 | $0.00 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 0% | 30 | $0.00 |
| J7030 | Infusion, normal saline solution , 1000 cc | 0% | 2,660 | $0.00 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 0% | 1,119 | $0.00 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | 0% | 1,552 | $0.00 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 0% | 78 | $0.00 |
| 87420 | 0% | 20 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialHOUGHTON, MARINA (CFO)
Parent organizationBORGESS MEDICAL CENTER
| Provider | Location | Paid |
|---|---|---|
| Ascension Borgess Hospital | Kalamazoo, MI | $43.08M |
| Ascension Medical Group Promed | Kalamazoo, MI | $10.60M |
| Ascension Medical Group Promed | Portage, MI | $7.97M |
| Ascension Borgess Lee Hospital | Dowagiac, MI | $6.88M |
| Ascension Borgess Allegan Hospital | Allegan, MI | $6.03M |
| Ascension Borgess Allegan Hospital | Allegan, MI | $3.71M |
| Ascension Borgess Hospital | Plainwell, MI | $3.71M |
| Ascension Borgess Lee Hospital | Dowagiac, MI | $2.70M |
| Ascension Medical Group Promed | Kalamazoo, MI | $2.55M |
| Ascension Medical Group Promed | Portage, MI | $2.07M |
| Ascension Medical Group Promed | Portage, MI | $1.64M |
| Ascension Borgess Lee Hospital | Dowagiac, MI | $1.58M |
| Ascension Borgess Hospital | Portage, MI | $1.22M |
| Ascension Borgess Allegan Hospital | Gobles, MI | $298K |
| Ascension Borgess Allegan Hospital | Otsego, MI | $294K |
| Ascension Borgess Allegan Hospital | Fennville, MI | $246K |
| Ascension Borgess Hospital | Kalamazoo, MI | $91K |
| Ascension Borgess Allegan Hospital | Allegan, MI | $55K |
| Ascension Borgess Allegan Hospital | Allegan, MI | $43K |
| Ascension Borgess Hospital | Kalamazoo, MI | $40K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.